# Comparison Study of a New Combination of 2 Marketed Medications (Esomeprazole and Naprosyn) Versus Naprosyn Alone

> **NCT00992381** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 24 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** PN400
- **DRUG:** Naprosyn

## Key facts

- **NCT ID:** NCT00992381
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** —
- **Final completion:** 2009-10
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2010-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00992381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00992381, "Comparison Study of a New Combination of 2 Marketed Medications (Esomeprazole and Naprosyn) Versus Naprosyn Alone". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00992381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*